Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 51 to 75 of 383

Sort by

Type: GuidanceRemove Type: Guidance filter
Type: Quality standardRemove Type: Quality standard filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]	Technology appraisal guidance	TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]	Technology appraisal guidance	13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]	Technology appraisal guidance	TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370	Technology appraisal guidance	TBC
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]	Technology appraisal guidance	23 October 2024
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure	NICE guideline	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]	Technology appraisal guidance	TBC
Cladribine for treating relapsing multiple sclerosis ID6263	Technology appraisal guidance	5 February 2025
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]	Technology appraisal guidance	TBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment	Health technology evaluation	TBC
Colon cancer (adjuvant) - irinotecan [ID379]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]	Technology appraisal guidance	16 October 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]	Technology appraisal guidance	30 October 2024
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack	Diagnostics guidance	10 July 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]	Technology appraisal guidance	29 May 2024
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]	Technology appraisal guidance	17 July 2024
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]	Technology appraisal guidance	TBC

Results per page

10
25
50
All